Fig. 4

Representative images of the patient’s target lesion (liver) following [¹⁷⁷Lu]Lu-DOTA-TATE therapy, showing a partial response (arrows). A Pre-therapeutic [⁶⁸Ga]Ga-DOTA-TOC PET/CT exhibited a target lesion uptake in the liver that was more intense than normal liver uptake (Krenning score 3). B The lesion’s largest diameter measured 72.8 mm on pre-therapeutic CECT. After four cycles of [¹⁷⁷Lu]Lu-DOTA-TATE therapy, C [¹⁷⁷Lu]Lu-DOTA-TATE SPECT/CT, captured after the fourth PRRT cycle (SPECT/CT images after PRRT cycles 1–3 are not shown), revealed target lesion uptake in the liver that was more intense than normal liver uptake (Krenning score 3). The cumulative tumour-absorbed Dose_max, Dose_peak, and Dose₄₁ of the target lesions were 157.8, 150.7, and 101.2 Gy, respectively. Following PRRT, the target lesion’s longest diameter decreased by > 30%, measuring 43.8 mm on (D) post-therapeutic CECT